Clinical trials located in

Swindon

Swindon city is located in United Kingdom. Currently, 1 clinical trials are being conducted in this city.

Swindon, located in southwest England, is a city with a rich industrial heritage, notably as a railway town since the mid-19th century. It houses the Steam Museum, celebrating its railway history. Swindon is also home to the Magic Roundabout, an innovative and complex road system consisting of five mini-roundabouts arranged in a circle. The city is surrounded by the scenic landscapes of the Wiltshire Downs. Additionally, Swindon has made significant contributions to literature and music, with connections to famous figures and bands.

  • CT-EU-00115114

    Evaluating Ianalumab for active Sjogren’s syndrome

    The NEPTUNUS-2 study is a significant research project aimed at exploring the effectiveness and safety of a medication called ianalumab (VAY736) for individuals suffering from active Sjogren’s Syndrome. This study is designed as a three-arm, randomized, double-blind, placebo-controlled trial, which means participants will be randomly assigned to one of three groups: two will receive ianalumab at different intervals, and one will receive a placebo, with neither the participants nor the researchers knowing which group participants are in to ensure unbiased results.

    The main goal of this study is to determine how well ianalumab can improve the symptoms of Sjogren’s Syndrome compared to a placebo. This will be measured by the change in a specific score called the EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) from the start of the study to week 48. The ESSDAI score helps doctors understand how active the disease is, with a higher score indicating more active disease. A decrease in this score over time would suggest an improvement in the condition.

    Participants in this study will receive ianalumab injections either once a month or every three months, depending on the group they are assigned to. The study emphasizes not only the potential benefits of ianalumab in treating Sjogren’s Syndrome but also its safety and tolerability, ensuring that the treatment is not only effective but also safe for patients.

See more clinical trials in other cities in United Kingdom:

.